Optimization of detection of cytomegalovirus viremia in transplantation recipients by shell vial assay.
AUTOR(ES)
Patel, R
RESUMO
Cytomegalovirus (CMV) viremia is a widely used laboratory marker of CMV disease following transplantation and is additionally used to trigger preemptive antiviral therapy. Despite this, the optimal method for diagnosing CMV viremia in transplantation recipients remains unknown. To determine the sampling frequency and blood volume required for the optimal diagnosis of viremia by shell vial assay, a prospective study of 46 viremic transplantation recipients was conducted. Blood specimens (2.5 and 5 ml) were collected twice, 3 h apart, at a median of 1.4 days (range, 1 to 3 days) after the triggering shell vial-positive blood had been collected. Considering a single 2.5-ml specimen, an average of only 40% of previously viremic patients had documented CMV in their blood: this increased to 50% when a second 2.5-ml sample of blood was collected 3 h later. The yields of two 2.5-ml versus two 5-ml samples were 50 versus 61%, respectively. Viremia as detected by shell vial assay is intermittent, and increasing the frequency and volume of blood sampling increases its diagnosis. These results have implications in diagnosis of CMV infection and its preemptive therapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=228619Documentos Relacionados
- Rapid detection of polyomavirus BK by a shell vial cell culture assay.
- Use of a modified shell vial technique to quantitate cytomegalovirus viremia in a population of solid-organ transplant recipients.
- Comparison of cytomegalovirus antigenemia assay with shell vial-indirect immunofluorescence assay for rapid detection of cytomegalovirus in blood.
- Detection of enteroviruses from clinical specimens by spin amplification shell vial culture and monoclonal antibody assay.
- Evaluation of the Murex Hybrid Capture Cytomegalovirus DNA Assay versus Plasma PCR and Shell Vial Assay for Diagnosis of Human Cytomegalovirus Viremia in Immunocompromised Patients